---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-020816"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:20:09.959324+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# bioAffinity reports CyPath Lung test volume up 111% in Oct vs 2025 monthly avg

## Summary
- October test volume increased 111% over 2025 monthly average; Q3 volume rose 95% sequentially.
- Medical practices with multiple CyPath orders rose 106% QoQ in Q3 and 67% in Oct vs YTD monthly avg.
- CyPath Lung noninvasive sputum test uses AI/flow cytometry; clinical study showed 92% sensitivity, 87% specificity.
- CEO Maria Zannes cites growing physician trust and successful outreach to pulmonologists, health systems, VA centers.

## SEC filing metadata
- accession: 0001493152-25-020816
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315225020816/0001493152-25-020816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315225020816/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-020816
- JSON: https://secwatch.observer/filing/0001493152-25-020816.json
- Plain text: https://secwatch.observer/filing/0001493152-25-020816.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.